Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Monday 09 July, 2001

Xenova Group PLC

Research Update

Xenova Group PLC
9 July 2001

                                                       FOR IMMEDIATE RELEASE

                                Xenova Group plc

            Anti-Cocaine Addiction Vaccine Released from Clinical Hold

                       Phase IIa Study Results Announced

Slough, UK, 9th July 2001 - Xenova Group plc (Nasdaq NM: XNVA; London Stock
Exchange: XEN) today announces that, following a US Food and Drug
Administration (FDA) review of the Company's recently submitted toxicology and
clinical study results, the FDA has notified Xenova that its TA-CD
(anti-cocaine addiction vaccine) product candidate has been released from
clinical hold with immediate effect.

The TA-CD Phase IIa study had been placed on precautionary hold in August 2000
following the observation that a related product caused eye irritation in
preclinical studies.  No such effects were observed with TA-CD in man and
extensive further testing of the related product has shown no safety
implications.  These results were submitted to the FDA in May 2001 and,
following FDA review, the clinical hold on the TA-CD IND has been removed.

TA-CD is designed to work by generating antibodies in the bloodstream, thus
preventing cocaine from crossing from the bloodstream into the brain and
stopping cocaine from blocking dopamine uptake, which is the cause of the '
high' that addicts obtain. Patients may therefore be expected to benefit most
from the support offered by TA-CD during the approximately 9 month period
which it takes for the addiction craving for cocaine to be lost.

Phase IIa trial results  - It is also announced today that the successful
results of this Phase IIa trial have been presented at the 63rd Annual
Scientific Meeting of the College on Problems of Drug Dependence, in Arizona,
USA.  The nine-patient study, in outpatient cocaine addicts, was conducted by
Dr Thomas Kosten, Professor of Psychiatry, Yale University School of Medicine
and was designed to evaluate the safety and immunogenicity of TA-CD using a
four-dose accelerated vaccination schedule.

TA-CD was shown to be well tolerated systemically and locally and was able to
generate higher and earlier antibody titres than those seen in a Phase I
34-patient trial using a three-dose vaccination schedule, potentially
benefiting the patient by establishing a more rapid therapeutic effect.
Cocaine specific antibodies persisted throughout the 12 weeks of the study.
No cocaine metabolites were detected in the urine of 5 out of the 8 evaluable
patients involved in the study, indicating no further cocaine use.  An
attenuation of the usual euphoric effects of cocaine was reported amongst
patients who relapsed during the study, providing anecdotal evidence of the
benefit TA-CD may provide.

Dr Kosten commented:  'We are delighted by the progress to date of this
potentially valuable product.  TA-CD was well tolerated in this trial and has
shown encouraging indications of efficacy.  It is very hard for cocaine
addicts to quit and TA-CD shows promise as a potential therapy.  TA-CD
certainly warrants further clinical investigation.'

Xenova expects to begin a new Phase II cocaine challenge study in the US in
the near future.  Addicts will be given cocaine under controlled conditions
before and after vaccination with TA-CD and their behaviour monitored.  Blood
samples will be taken for the measurement of antibody titres.  The purpose of
the study is to provide an assessment of the efficacy of TA-CD, as determined
by quantitative behavioural and other measurements.

This study is being funded in part by the US National Institute on Drug Abuse
(NIDA).  NIDA have also supported earlier Phase l/lla work as part of this

David Oxlade, Chief Executive of Xenova, commented: 'There is a real societal
need for a solution to the problems of drug abuse and addiction, with an
estimated 900,000 people seeking treatment for cocaine addiction every year in
the US alone.  Following the encouraging results of this trial we will now be
evaluating the efficacy of TA-CD in cocaine addicts.'



Xenova Group plc                                   Financial Dynamics
Tel: +44 (0) 1753 706600                           Tel: +44(0) 207 831 3113
David Oxlade: Chief Executive Officer              David Yates/Fiona Noblet
Daniel Abrams: Finance Director
Hilary Reid Evans: Corporate Communications

                               Notes to Editors

Xenova Group plc's product pipeline focuses principally on the therapeutic
areas of cancer, infectious diseases and addiction.  The Group has a
well-established track record in the identification, development and
partnering of innovative products and technologies.  The Group has
partnerships with a number of major pharmaceutical companies including Glaxo
SmithKline, Lilly, Pfizer and Celltech.

For further information about Xenova and its products please visit the Xenova
                         website at


a d v e r t i s e m e n t